Cargando…

Evaluation of the use of methylprednisolone and dexamethasone in asthma critically ill patients with COVID-19: a multicenter cohort study

BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asth...

Descripción completa

Detalles Bibliográficos
Autores principales: Al Sulaiman, Khalid, Aljuhani, Ohoud, Korayem, Ghazwa B., Altebainawi, Ali, Alharbi, Reham, Assadoon, Maha, Vishwakarma, Ramesh, Ismail, Nadia H., Alshehri, Asma A., Al Mutairi, Faisal E., AlFaifi, Mashael, Alharthi, Abdullah F., Alenazi, Abeer A., Alalawi, Mai, Al Zumai, Omar, Al Haji, Hussain, Al Dughaish, Sarah T., Alawaji, Abdulrahman S., Alhaidal, Haifa A., Al Ghamdi, Ghassan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463591/
https://www.ncbi.nlm.nih.gov/pubmed/37641042
http://dx.doi.org/10.1186/s12890-023-02603-4
Descripción
Sumario:BACKGROUND: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not been extensively evaluated in patients with a history of asthma. This study aims to investigate and compare the effectiveness and safety of methylprednisolone and dexamethasone in critically ill patients with asthma and COVID-19. METHODS: The primary endpoint was the in-hospital mortality. Other endpoints include 30-day mortality, respiratory failure requiring mechanical ventilation (MV), acute kidney injury (AKI), acute liver injury, length of stay (LOS), ventilator-free days (VFDs), and hospital-acquired infections. Propensity score (PS) matching, and regression analyses were used. RESULTS: A total of one hundred-five patients were included. Thirty patients received methylprednisolone, whereas seventy-five patients received dexamethasone. After PS matching (1:1 ratio), patients who received methylprednisolone had higher but insignificant in-hospital mortality in both crude and logistic regression analysis, [(35.0% vs. 18.2%, P = 0.22) and (OR 2.31; CI: 0.56 – 9.59; P = 0.25), respectively]. There were no statistically significant differences in the 30-day mortality, respiratory failure requiring MV, AKI, acute liver injury, ICU LOS, hospital LOS, and hospital-acquired infections. CONCLUSIONS: Methylprednisolone in COVID-19 patients with asthma may lead to increased in-hospital mortality and shorter VFDs compared to dexamethasone; however, it failed to reach statistical significance. Therefore, it is necessary to interpret these data cautiously, and further large-scale randomized clinical trials are needed to establish more conclusive evidence and support these conclusions. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12890-023-02603-4.